-
公开(公告)号:US09717738B2
公开(公告)日:2017-08-01
申请号:US15132122
申请日:2016-04-18
IPC分类号: A61K31/397 , A61K31/535 , A61P11/06 , A61K31/5383 , A61K9/00 , A61K31/4375 , A61K31/47 , A61K31/538 , A61K47/02 , A61K31/536
CPC分类号: A61K31/5383 , A61K9/0073 , A61K9/0078 , A61K31/4375 , A61K31/47 , A61K31/536 , A61K31/538 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
-
2.
公开(公告)号:US20160287606A1
公开(公告)日:2016-10-06
申请号:US15132122
申请日:2016-04-18
IPC分类号: A61K31/5383 , A61K47/02 , A61K9/00
CPC分类号: A61K31/5383 , A61K9/0073 , A61K9/0078 , A61K31/4375 , A61K31/47 , A61K31/536 , A61K31/538 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
摘要翻译: 本发明涉及抗微生物剂领域。 特别地,本发明涉及用二价或三价阳离子配制的雾化氟喹诺酮类药物,并且具有改善的肺可用性,用于治疗和管理肺和上呼吸道的细菌感染。
-
3.
公开(公告)号:US09326936B2
公开(公告)日:2016-05-03
申请号:US14333583
申请日:2014-07-17
IPC分类号: A61K31/397 , A61K31/535 , A61P11/06 , A61K9/00 , A61K31/4375 , A61K31/47 , A61K31/538 , A61K47/02 , A61K31/536
CPC分类号: A61K31/5383 , A61K9/0073 , A61K9/0078 , A61K31/4375 , A61K31/47 , A61K31/536 , A61K31/538 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
摘要翻译: 本发明涉及抗微生物剂领域。 特别地,本发明涉及用二价或三价阳离子配制的雾化氟喹诺酮类药物,并且具有改善的肺可用性,用于治疗和管理肺和上呼吸道的细菌感染。
-
公开(公告)号:US20160279138A1
公开(公告)日:2016-09-29
申请号:US15173372
申请日:2016-06-03
IPC分类号: A61K31/5383 , A61K47/02 , A61K9/00
CPC分类号: A61K31/5383 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/5123 , A61K47/02 , Y02A50/401 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/483
摘要: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
摘要翻译: 本文公开了适用于气雾化和使用这种制剂的氟喹诺酮类制剂用于气雾剂施用氟喹诺酮抗微生物剂以治疗肺细菌感染。 特别地,描述了专门配制并递送用于肺细菌感染的吸入性左氧氟沙星。 方法包括用于生产和使用所述组合物的吸入方案和制造方法。
-
-
-